SEATTLE - Sana Biotechnology, Inc. (NASDAQ: SANA), a cell engineering company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational therapy SC291 for patients with relapsed/refractory systemic lupus erythematosus (SLE). The Fast Track process aims to accelerate the development and review of drugs intended to treat serious conditions and fulfill an unmet medical need. According to InvestingPro data, while Sana maintains a strong liquidity position with a current ratio of 4.47, the company faces significant cash burn challenges as it advances its clinical programs.
SC291 is a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy. It is currently being evaluated in the company’s GLEAM trial, targeting B-cell mediated autoimmune diseases, including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana has begun enrolling patients in the trial and anticipates sharing initial clinical data in 2025.
The Chief Scientific Officer of Sana, Dhaval Patel, M.D., Ph.D., noted the Fast Track designation underscores the urgent need for new treatments for SLE and expressed optimism about the potential of SC291 to be a universal off-the-shelf therapy. SC291 is designed to target CD19, a protein found on B cells, which are implicated in the pathology of many autoimmune diseases. CD19-directed CAR T therapy offers a novel approach where the CAR T cells act as the agents that deplete B cells throughout the body.
Sana Biotechnology focuses on developing engineered cell therapies for various diseases. The company operates out of several locations in the United States, including Seattle, Cambridge, South San Francisco, Bothell, and Rochester.
While the press release contains forward-looking statements regarding the potential of SC291 as a therapy for SLE and the anticipated timing for initial data from the GLEAM trial, these statements are subject to risks and uncertainties that could affect the actual outcomes. The company's progress, including its research and development programs, is subject to the inherent risks of drug development and potential economic and market disruptions. InvestingPro analysis shows the stock has experienced significant volatility, with a 12.1% gain in the past week despite a 62.9% decline over six months. The company's current market capitalization stands at $620.7 million, with analysts maintaining mixed outlooks on its prospects.
This article is based on a press release statement from Sana Biotechnology. The company has not provided any new data or findings that are independently verifiable at this time. For deeper insights into Sana's financial health and detailed analysis, investors can access comprehensive research reports and additional ProTips through InvestingPro, which currently rates the company's overall financial health as "Fair" with a score of 2.02 out of 5.
In other recent news, Sana Biotechnology has announced a strategic restructuring of its pipeline, prioritizing its UP421 and SC451 programs for Type 1 diabetes (T1D), and its SC291 program for B-cell driven autoimmune diseases. The company has de-prioritized its SC291 program for B-cell malignancies and its glial progenitor cell program, and is seeking a licensing partner for these programs. The anticipated data for the company's clinical programs are now expected in the fourth quarter of 2024 or in 2025. H.C. Wainwright has maintained a Buy rating on Sana Biotechnology, while JMP Securities has downgraded the company's stock from Market Outperform to Market Perform. The company's CFO, Nathan Hardy, will step down in October 2024, and Dhaval Patel, M.D., Ph.D., has been appointed as the new Executive Vice President and Chief Scientific Officer. Citi has increased its price target for Sana from $8.00 to $15.00 due to progress in its T1D trial. These are the recent developments regarding Sana Biotechnology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.